A case of hair dye‐induced allergic contact dermatitis in the context of nivolumab.

Keywords: 4-phenylenediamine; dermatitis; allergic contact; drug-related side effects and adverse reactions; immunotherapy; patch tests EN 4-phenylenediamine dermatitis allergic contact drug-related side effects and adverse reactions immunotherapy patch tests 377 379 3 09/08/22 20221001 NES 221001 Abbreviations ACD allergic contact dermatitis CTLA-1 cytotoxic T-lymphocyte associated protein 4 ICP immune check points ICPI immune check point inhibitor IRAE immune-related adverse events MI methylisothiazolinone PD-1 programmed cell death protein 1 PDL1 programmed death ligand 1 PPD para-phenylenediamine Treg T regulatory cells Allergic contact dermatitis (ACD) arising during immune check point inhibitor (ICPI) therapy has rarely been reported and is likely an under-recognized cause of a number of cutaneous immune-related adverse events (IRAE), especially treatment refractory dermatitic eruptions. Dermatitis, allergic contact, drug-related side effects and adverse reactions, 4-phenylenediamine, immunotherapy, patch tests Just as immunosuppression risks false-negative results,7 an immune-enhanced anti-PD-1 state could theoretically cause allergy induction, severe patch test reactions and false positives. [Extracted from the article]